A Phase 4 interventional study of Budesonide/formoterol in Asthma, sponsored by AstraZeneca. Completed at 819 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-22.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one has the largest enrollment of the 108 interventional ones that give a count, is one of 12 that started in 2007, is one of 33 in phase 4, and was the 25th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8,424 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 2nd largest by enrollment of the 248 interventional ones that give a count, is one of 18 that started in 2007, is one of 23 in phase 4, and was the 56th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of two different maintenance doses of Symbicort Maintenance And Reliever Therapy (SMART) in adult asthmatic patients. A 6 month treatment period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug pages: Budesonide · Formoterol
Number of Severe Asthma Exacerbations Per Participant.
Time to first severe asthma exacerbation, translated to mean number of severe asthma exacerbations per participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.
Time frame: 6 months
Fraction of Participants With Severe Asthma Exacerbation
The total number of severe asthma exacerbations was calculated for each participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.
Time frame: 6 months.
Total Number of Severe Asthma Exacerbations That Led to Hospitalisation and/or Emergency Room Treatment.
A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment. Number of events per participant
Time frame: 6 months.
Total Number of Days Per Participant With Oral/Systemic Glucocorticosteroids During Severe Asthma Exacerbation
Total number of days with oral/systemic glucocorticosteroids during severe exacerbation calculated for each participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.
Time frame: 6 months.
Mean Daily Number of Inhalations of As-needed Medication.
The number of as-needed inhalations was measured 2 times during 2 weeks before 13 weeks and 26 weeks of treatment.
Time frame: 4 weeks
Percent of Participants With a Well Controlled Asthma Week.
The mean percent of participants fulfilling the criteria for a well controlled asthma week in each treatment. A well controlled asthma week is defined as a week with no exacerbations and no night-time awakenings due to asthma and a maximum of 2 days with symptoms and as-needed inhalation use.
Time frame: 6 months.
Mean Overall Asthma Control Questionnaire (ACQ) Score
The ACQ5 was used. The lower value the better with a full range from 0=no impairment, 6= maximum impairment. Awakenings, morning symptoms, limitations, shortness of breath and wheeze.
Time frame: 6 months.
The Mean Total Daily Dose of Steroids From Symbicort.
The mean total daily dose of steroids from Symbicort was calculated as the sum of the maintenance dose and the as-needed dose.
Time frame: 4 weeks
Mean Cost Per Participant Per Country
Mean cost is calculated for each country using participants from the whole study and country specific costs. Mean value for the whole study can not be calculated.
Time frame: 6 months
This was a 6-month, randomised, open label, parallel-group, active controlled, multinational study, in participants with uncontrolled/partly controlled asthma, who were symptomatic despite daily use of inhaled glucocorticosteroid (IGCS) with or without Long-Acting β2 agonist (LABA).
| Milestone | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| Started | 4008 | 4045 |
| Completed | 3699 | 3705 |
| Not completed | 309 | 340 |
| Withdrew: Adverse event | 70 | 93 |
| Withdrew: Withdrawal by subject | 81 | 79 |
| Withdrew: Lost to follow-up | 46 | 55 |
| Withdrew: Incorrect enrolment | 64 | 66 |
| Withdrew: Severe non-compliance to protocol | 25 | 21 |
| Withdrew: Safety reason | 1 | 3 |
| Withdrew: Mis-randomization of subject | 0 | 1 |
| Withdrew: Other | 22 | 22 |
Time to first severe asthma exacerbation, translated to mean number of severe asthma exacerbations per participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.
| Severe exacerbations per participant | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| Number of Severe Asthma Exacerbations Per Participant. | 0.097 ± 0 | 0.080 ± 0 |
The total number of severe asthma exacerbations was calculated for each participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.
| Fraction of participants with event | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| Fraction of Participants With Severe Asthma Exacerbation | 0.09686 ± 0.08528 | 0.07955 ± 0.06927 |
A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment. Number of events per participant
| Number of events per participant | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| Total Number of Severe Asthma Exacerbations That Led to Hospitalisation and/or Emergency Room Treatment. | 0.0120 ± 0 | 0.0091 ± 0 |
Total number of days with oral/systemic glucocorticosteroids during severe exacerbation calculated for each participant. A severe asthma exacerbation is defined as deterioration in asthma requiring oral/systemic glucocorticosteroids for at least 3 days and/or hospitalisation/emergency room visit with oral/systemic glucocorticosteroid treatment.
| Days per participant | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| Total Number of Days Per Participant With Oral/Systemic Glucocorticosteroids During Severe Asthma Exacerbation | 9.6 ± 8.1 | 9.1 ± 5.5 |
The number of as-needed inhalations was measured 2 times during 2 weeks before 13 weeks and 26 weeks of treatment.
| Inhalations per day per participant | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| Mean Daily Number of Inhalations of As-needed Medication. | 0.897 ± 0 | 0.625 ± 0 |
The mean percent of participants fulfilling the criteria for a well controlled asthma week in each treatment. A well controlled asthma week is defined as a week with no exacerbations and no night-time awakenings due to asthma and a maximum of 2 days with symptoms and as-needed inhalation use.
| Percentage of participants | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| Percent of Participants With a Well Controlled Asthma Week. | 43.69 ± 0 | 54.26 ± 0 |
The ACQ5 was used. The lower value the better with a full range from 0=no impairment, 6= maximum impairment. Awakenings, morning symptoms, limitations, shortness of breath and wheeze.
| Scores in a scale | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| Mean Overall Asthma Control Questionnaire (ACQ) Score | 1.18 ± 0 | 1.089 ± 0 |
The mean total daily dose of steroids from Symbicort was calculated as the sum of the maintenance dose and the as-needed dose.
| μg budesonide per day | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| The Mean Total Daily Dose of Steroids From Symbicort. | 462.96 ± 179.10 | 736.58 ± 152.70 |
Mean cost is calculated for each country using participants from the whole study and country specific costs. Mean value for the whole study can not be calculated.
Results for this outcome have not been posted.
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symbicort® SMART®) 1*2 | — | 77/4,008 (1.9%) | 0/4,008 (0%) |
| Symbicort® SMART®) 2*2 | — | 88/4,045 (2.2%) | 0/4,045 (0%) |
| Event | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 13/4008 | 9/4045 |
| CholelithiasisHepatobiliary disorders | 0/4008 | 4/4045 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4008 | 4/4045 |
| PneumoniaInfections and infestations | 3/4008 | 3/4045 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 3/4008 | 3/4045 |
| Atrial FibrillationCardiac disorders | 2/4008 | 1/4045 |
| ColitisGastrointestinal disorders | 2/4008 | 0/4045 |
| DiarrhoeaGastrointestinal disorders | 2/4008 | 0/4045 |
| Chest PainGeneral disorders | 2/4008 | 1/4045 |
| CataractEye disorders | 0/4008 | 2/4045 |
| Age Continuous(Years) | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 | Total |
|---|---|---|---|
| Mean | 47.8 (18 to 96) | 47.9 (18 to 90) | 47.8 (18 to 96) |
| Sex: Female, Male(Participants) | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 | Total |
|---|---|---|---|
| Female | 2483 | 2512 | 4995 |
| Male | 1525 | 1533 | 3058 |
| Treatment with Long-Acting β2 agonist (LABA) at baseline.(Participants) | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 | Total |
|---|---|---|---|
| Number of participants using LABA at baseline. | 3108 | 3118 | 6226 |
| Number of participants without LABA at baseline. | 900 | 927 | 1827 |
| Asthma control questionnaire (ACQ5) score at study entry(Units on a scale) | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 | Total |
|---|---|---|---|
| ACQ5 score at study entry | 1.85 ± 0.98 | 1.86 ± 1.01 | 1.85 ± 0.99 |
| Exacerbations past 12 months before study start.(Number of exacerbations per participant) | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 | Total |
|---|---|---|---|
| Mean | 1.47 ± 2.42 | 1.42 ± 2.42 | 1.45 ± 2.42 |
| Inhaled glucocorticosteroids (IGCS) dose at study entry.(μg/day) | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 | Total |
|---|---|---|---|
| IGCS dose at study entry | 1046 ± 595 | 1037 ± 575 | 1042 ± 585 |
| Participants with a well controlled asthma week at study entry.(Percentage of participants) | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 | Total |
|---|---|---|---|
| Mean | 11.97 (0 to 100) | 11.77 (0 to 100) | 11.87 (0 to 100) |
| Pulmonary function test at baseline.(Percent of predicted normal value of PEF) | Symbicort® SMART®) 1*2 | Symbicort® SMART®) 2*2 | Total |
|---|---|---|---|
| Percent Included | 90.8 (0 to 100) | 90.1 (0 to 100) | 90.4 (0 to 100) |
Showing the first 100 of 819 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2007 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Formoterol